

## asx announcement

### **FORMER JOHNSON & JOHNSON VICE CHAIRMAN JOINS ANGIOBLAST BOARD OF DIRECTORS**

**Melbourne, Australia; 30 October 2007:** Australia's adult stem cell company, Mesoblast Limited (ASX:MSB;USOTC:MBLTY), today announced that Robert E. Campbell, the former Chief Financial Officer and Vice Chairman of Johnson & Johnson, has been appointed to the Board of Directors of its United States-based sister company, Angioblast Systems Inc.

Mr Campbell has been appointed head of the Board's Audit Committee, a role in which he will oversee the company's fiduciary governance as the company transitions to full compliance with Sarbanes-Oxley US capital market regulations.

At Johnson & Johnson, Mr Campbell was Chairman of the Professional Sector Worldwide, overseeing the development of the company's medical devices, including cardiovascular stents, endo-surgery instruments, and disposable contact lenses. Today Johnson & Johnson is one of the world's largest medical device and pharmaceutical corporations with a market capitalisation of over \$US 180 billion. Mr Campbell is currently a Trustee and past Chairman of the Board of The Robert Wood Johnson Foundation, one of the largest philanthropic organisations in the US with an endowment of approximately \$US 10 billion. He is also Trustee Emeritus and past Chairman of the Board of Fordham University.

Mesoblast's Board of Directors is delighted with Mr Campbell's appointment, and believes that his strategic, corporate, and financial expertise will significantly enhance Angioblast's ability to execute on its strategic partnering initiatives, corporate milestones, and capital markets opportunities.

#### **About Mesoblast:**

Mesoblast Limited (ASX:MSB;USOTC:MBLTY) is an Australian biotechnology company committed to the development of novel treatments for orthopaedic conditions, including the rapid commercialisation of a unique adult stem cell technology aimed at the regeneration and repair of bone and cartilage. Our focus is to progress through clinical trials and international regulatory processes necessary to commercialise the technology in as short a timeframe as possible. Mesoblast has the worldwide exclusive rights for a series of patents and technologies that have been developed over more than 10 years and which relate to the identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs). The company has also acquired a substantial interest in Angioblast Systems Inc, an American company developing the platform MPC technology for the treatment of cardiovascular diseases, including repair and regeneration of blood vessels and heart muscle. Mesoblast and Angioblast are jointly funding and progressing the core technology. Mesoblast's strategy is to maximise shareholder value through both corporate partnerships and the rapid and successful completion of clinical milestones.

*For further information, please contact:*

Julie Meldrum  
Corporate Communications Director  
T: + 61 (03) 9639 6036 M: +61 (0) 419 228 128  
E: [julie.meldrum@mesoblast.com](mailto:julie.meldrum@mesoblast.com)